Meeting
2022 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).
Authors
Ezra Rosen
Memorial Sloan Kettering Cancer Center, New York, NY
Ezra Rosen , Ian M. Silverman , Elisa Fontana , Elizabeth Katherine Lee , David R. Spigel , Martin Højgaard , Stephanie Lheureux , Niharika B. Mettu , Benedito A. Carneiro , Louise Carter , Elizabeth Ruth Plummer , Joseph D. Schonhoft , Danielle Ulanet , Peter Manley , Jorge S. Reis-Filho , Yi Xu , Victoria Rimkunas , Maria Koehler , Timothy A. Yap
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04497116
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3082)
DOI
10.1200/JCO.2022.40.16_suppl.3082
Abstract #
3082
Poster Bd #
74
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Frequencies of actionable alterations found by somatic tumor sequencing in veterans with metastatic prostate cancer.
First Author: Nicholas George Nickols
Poster
2021 ASCO Annual Meeting
Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.
First Author: Joseph W. Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.
First Author: Alexandra Androsova
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh